“…Given the mild clinical phenotype and high rates of incomplete penetrance associated with DCC ‐MMs and DCC ‐iACC, cascade testing should be considered for all extended family members at risk of inheriting a mutant allele. Differential genetic diagnoses for DCC ‐MMs include NTN1 and RAD51 (MIM# 179617) (Depienne et al., ; Méneret et al., ; Méneret et al., ); for DCC ‐iACC include CDK5RAP2 (MIM# 608201, although only one family has been described to date (Jouan et al., )); and for DSBS include ROBO3 (note: individuals with HGPPS1 do not suffer from intellectual disability and have normal forebrain commissures, consistent with the predominant role of ROBO3 in the developing hindbrain and spinal cord) (Chan et al., ; Jen et al., ; Sicotte et al., ). However, the low diagnostic yield of genetic screening studies indicates that additional MMs and iACC disease genes remain to be identified and therefore mutations in DCC , NTN1 , RAD51 , and CDK5RAP2 will not always be identified in individuals with these phenotypes (Franz et al., ; Jamuar et al., ; Marsh et al., ; Méneret et al., ; Méneret et al., ; Méneret, et al., ).…”